DAS-181

Summary

Das-181 (CHEMBL4297932) is a phase-3 clinical-stage unknown; indicated across 4 conditions including paramyxoviridae infectious disease and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297932
Name	DAS-181
Type	Unknown
Max phase	3

Also known as: Das-181, DAS-181F04, Das181, DAS181F04, Fludase, Oplunofusp, DAS-181

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Paramyxoviridae infectious disease	3	MONDO:0005896	EFO:0007419
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
influenza	2	MONDO:0005812	EFO:0007328

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	3
Not specified	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03808922	PHASE3	RECRUITING	Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT04354389	PHASE2/PHASE3	WITHDRAWN	DAS181 for STOP COVID-19
NCT01441024	PHASE2	WITHDRAWN	DAS181 in Patients With Parainfluenza
NCT01740063	PHASE2	COMPLETED	Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza
NCT04298060	PHASE2	UNKNOWN	DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
NCT00527865	PHASE1	COMPLETED	Single Dose Escalating Study of DAS181 in Adults
NCT00876161	PHASE1	COMPLETED	DAS181 Single Dose Escalation Study in Healthy Adults
NCT01173224	PHASE1	COMPLETED	Influenza Antiviral DAS181-F03
NCT01651494	PHASE1	COMPLETED	Influenza Antiviral DAS-181-F04 in Healthy Adults
NCT04324489	Not specified	COMPLETED	DAS181 for Severe COVID-19: Compassionate Use
NCT04460547	Not specified	UNKNOWN	Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).